Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SPTXthis companySeaport Therapeutics, Inc. Common Stock	$21.77	-10.23×	-8.29×	0×	-8.45×	-94.6%	0.0%	0.0%	0.0%	80.9%	-36.7%	-10.2%	-0.05×	0.48×	0×	17.46×	0.0%	—	—	2	C+
CTNMContineum Therapeutics, Inc.	$10.00	-5.27×	1.21×	0×	-3.68×	-74.9%	0.0%	0.0%	0.0%	-23.0%	-25.3%	-17.5%	0.03×	0.99×	0×	27.5×	0.0%	2	16.76	2	C+
KTTAPasithea Therapeutics Corp.	$0.61	-0.44×	0.16×	0×	2.28×	2031.8%	0.0%	0.0%	0.0%	-37.0%	-37.7%	-167.7%	0×	2.73×	0×	11.35×	0.0%	2	1.38	2	B-
LBRXLB Pharmaceuticals Inc Common Stock	$42.38	-22.26×	1.87×	0×	-12.72×	-75.2%	0.0%	0.0%	0.0%	-8.4%	-9.9%	-6.3%	0.01×	9.91×	0×	41.44×	0.0%	2	25.27	2	C+
MPLTMapLight Therapeutics, Inc.	$7.43	-4.8×	1.69×	0×	-4.56×	-86.3%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-17.9%	0.01×	0.25×	0×	20.01×	0.0%	2	5.7	2	C
NMRANeumora Therapeutics, Inc. Common Stock	$0.54	-1.23×	2.82×	0×	-0.47×	121.4%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.15	2	C+
Peer median	—	-4.8×	1.69×	0×	-3.68×	-74.9%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-17.9%	0.01×	0.99×	0×	20.01×	0.0%	2	5.7	2	—